180 related articles for article (PubMed ID: 31905966)
1. Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer.
Pan MR; Wu CC; Kan JY; Li QL; Chang SJ; Wu CC; Li CL; Ou-Yang F; Hou MF; Yip HK; Luo CW
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31905966
[TBL] [Abstract][Full Text] [Related]
2. Combination of FAK inhibitor and cytokine-induced killer cell therapy: An alternative therapeutic strategy for patients with triple-negative breast cancer.
Wu CC; Pan MR; Shih SL; Shiau JP; Wu CC; Chang SJ; Kao CN; Chen FM; Hou MF; Luo CW
Biomed Pharmacother; 2023 Jul; 163():114732. PubMed ID: 37254289
[TBL] [Abstract][Full Text] [Related]
3. Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1
Mohan N; Hosain S; Zhao J; Shen Y; Luo X; Jiang J; Endo Y; Wu WJ
Oncoimmunology; 2019; 8(9):e1624128. PubMed ID: 31428520
[TBL] [Abstract][Full Text] [Related]
4. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.
Sommaggio R; Cappuzzello E; Dalla Pietà A; Tosi A; Palmerini P; Carpanese D; Nicolè L; Rosato A
Oncoimmunology; 2020 Jun; 9(1):1777046. PubMed ID: 32923140
[TBL] [Abstract][Full Text] [Related]
5. Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells.
Rigiracciolo DC; Santolla MF; Lappano R; Vivacqua A; Cirillo F; Galli GR; Talia M; Muglia L; Pellegrino M; Nohata N; Di Martino MT; Maggiolini M
J Exp Clin Cancer Res; 2019 Feb; 38(1):58. PubMed ID: 30728047
[TBL] [Abstract][Full Text] [Related]
6. FAK Regulates VEGFR2 Expression and Promotes Angiogenesis in Triple-Negative Breast Cancer.
Shiau JP; Wu CC; Chang SJ; Pan MR; Liu W; Ou-Yang F; Chen FM; Hou MF; Shih SL; Luo CW
Biomedicines; 2021 Nov; 9(12):. PubMed ID: 34944605
[TBL] [Abstract][Full Text] [Related]
7. FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells.
Taliaferro-Smith L; Oberlick E; Liu T; McGlothen T; Alcaide T; Tobin R; Donnelly S; Commander R; Kline E; Nagaraju GP; Havel L; Marcus A; Nahta R; O'Regan R
Oncotarget; 2015 Mar; 6(7):4757-72. PubMed ID: 25749031
[TBL] [Abstract][Full Text] [Related]
8. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer.
Pan K; Guan XX; Li YQ; Zhao JJ; Li JJ; Qiu HJ; Weng DS; Wang QJ; Liu Q; Huang LX; He J; Chen SP; Ke ML; Zeng YX; Xia JC
Clin Cancer Res; 2014 Jun; 20(11):3003-11. PubMed ID: 24668644
[TBL] [Abstract][Full Text] [Related]
9. Targeting FAK/PYK2 with SJP1602 for Anti-Tumor Activity in Triple-Negative Breast Cancer.
Jeon M; Hong S; Cho H; Park H; Lee SM; Ahn S
Curr Issues Mol Biol; 2023 Aug; 45(9):7058-7074. PubMed ID: 37754230
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous inhibition of FAK and ROS1 synergistically repressed triple-negative breast cancer by upregulating p53 signalling.
Tan X; Kong D; Tao Z; Cheng F; Zhang B; Wang Z; Mei Q; Chen C; Wu K
Biomark Res; 2024 Jan; 12(1):13. PubMed ID: 38273343
[TBL] [Abstract][Full Text] [Related]
11. FAK tyrosine 407 organized with integrin αVβ5 in Hs578Ts(i)8 advanced triple-negative breast cancer cells.
Payan I; McDonnell S; Torres HM; Steelant WF; Van Slambrouck S
Int J Oncol; 2016 May; 48(5):2043-54. PubMed ID: 26984508
[TBL] [Abstract][Full Text] [Related]
12. PD-1 blockade enhances cytokine-induced killer cell-mediated cytotoxicity in B-cell non-Hodgkin lymphoma cell lines.
Li Y; Sharma A; Bloemendal MWJR; Schmidt-Wolf R; Kornek M; Schmidt-Wolf IGH
Oncol Lett; 2021 Aug; 22(2):613. PubMed ID: 34257721
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant treatment for triple-negative breast cancer: a retrospective study of immunotherapy with autologous cytokine-induced killer cells in 294 patients.
Zhang Y; Wang S; Yang B; Lu S; Du Y; Liu H
Cancer Biol Med; 2019 May; 16(2):350-360. PubMed ID: 31516755
[TBL] [Abstract][Full Text] [Related]
14. Carbon nanotubes (CNT)-loaded ginsenosides Rb3 suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer.
Luo X; Wang H; Ji D
Aging (Albany NY); 2021 Jun; 13(13):17177-17189. PubMed ID: 34111025
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel chloropyramine-cinnamic acid hybrids as potential FAK inhibitors for intervention of metastatic triple-negative breast cancer.
Yang F; Xu K; Zhang S; Zhang J; Qiu Y; Luo J; Tan G; Zou Z; Wang W; Kang F
Bioorg Med Chem; 2022 Jul; 66():116809. PubMed ID: 35569251
[TBL] [Abstract][Full Text] [Related]
16. IGF-1/IGF-1R/FAK/YAP Transduction Signaling Prompts Growth Effects in Triple-Negative Breast Cancer (TNBC) Cells.
Rigiracciolo DC; Nohata N; Lappano R; Cirillo F; Talia M; Scordamaglia D; Gutkind JS; Maggiolini M
Cells; 2020 Apr; 9(4):. PubMed ID: 32325700
[TBL] [Abstract][Full Text] [Related]
17. Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer.
Dai C; Lin F; Geng R; Ge X; Tang W; Chang J; Wu Z; Liu X; Lin Y; Zhang Z; Li J
Oncotarget; 2016 Mar; 7(9):10332-44. PubMed ID: 26871284
[TBL] [Abstract][Full Text] [Related]
18. Glutathione peroxidase-1 regulates adhesion and metastasis of triple-negative breast cancer cells via FAK signaling.
Lee E; Choi A; Jun Y; Kim N; Yook JI; Kim SY; Lee S; Kang SW
Redox Biol; 2020 Jan; 29():101391. PubMed ID: 31926619
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
Wang X; Liu Y
Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer.
Zhou ZQ; Zhao JJ; Pan QZ; Chen CL; Liu Y; Tang Y; Zhu Q; Weng DS; Xia JC
J Immunother Cancer; 2019 Aug; 7(1):228. PubMed ID: 31455411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
